



2-2013

Lysine Biosynthesis in Bacteria: A Metallo succinylase as a Potential Antimicrobial Target

Danuta M. Gillner

Silesian University of Technology

Daniel P. Becker Ph.D.

Loyola University Chicago, dbecke3@luc.edu

Richard C. Holz

Loyola University Chicago, rholz1@luc.edu

Author Manuscript

This is a pre-publication author manuscript of the final, published article.

Recommended Citation

Gillner, Danuta M.; Becker, Daniel P. Ph.D.; and Holz, Richard C.. Lysine Biosynthesis in Bacteria: A Metallo succinylase as a Potential Antimicrobial Target. *JBIC Journal of Biological Inorganic Chemistry*, 18, 2: 155-163, 2013. Retrieved from Loyola eCommons, Chemistry: Faculty Publications and Other Works, <http://dx.doi.org/10.1007/s00775-012-0965-1>

This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has been accepted for inclusion in Chemistry: Faculty Publications and Other Works by an authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.



This work is licensed under a [Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License](https://creativecommons.org/licenses/by-nc-nd/3.0/).

© 2012 SBIC

Lysine Biosynthesis in Bacteria:

A Metallodesuccinylase as a Potential Antimicrobial Target

Danuta M. Gillner^{1,2*}, Daniel Becker¹, and Richard C. Holz^{1*}

Contribution from the Department of Chemistry and Biochemistry, Loyola University-Chicago, 1068 W. Sheridan Rd., Chicago, IL 60626 and the Department of Chemistry, Silesian University of Technology, ul. Krzywoustego 4, 44-100 Gliwice, Poland

Running Title: *dapE*-encoded *N*-succinyl-L,L-diaminopimelic acid desuccinylase

¹Loyola University Chicago, ²Silesian University of Technology


†This work was supported by the National Institutes of Health (R15 AI085559-01A1, RCH).

*Address correspondence to: Richard C. Holz, Department of Chemistry, Loyola University-Chicago, 1068 W. Sheridan Rd., Chicago, IL 60626, Phone (773) 508-3092, Fax: (773) 508-3086, Internet: rholtz1@luc.edu or Danuta M. Gillner, Department of Chemistry, Silesian University of Technology, ul. Krzywoustego 4, 44-100 Gliwice, Poland, Phone +48 32 237 27 91, Fax: +48 32 237 10 32, Internet: Danuta.Gilner@polsl.pl.

Antibiotic Resistance

Abstract

In this review, we summarize the recent literature on the *dapE*-encoded *N*-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) enzymes with an emphasis on structure-function studies, which have provided insight into the catalytic mechanism of DapE enzymes. Crystallographic data has also provided insight into residues that might be involved in substrate, and hence inhibitor recognition and binding. These data have led to the design and synthesis of several new DapE inhibitors, which are described along with what is known about how inhibitors interact with the active site of DapE enzymes including the efficacy of a moderately strong DapE inhibitor.



Key Words: DapE, Metallohydrolase, Antibiotics, Zinc, X-ray Crystallography, Inhibitor Design, Catalytic Mechanism.

The emergence of antibiotic-resistant bacterial infections has created a significant and growing medical problem in the United States and throughout the world [1-5]. Antibiotic resistance has been recognized since the introduction of penicillin more than 50 years ago when penicillin-resistant infections caused by *Staphylococcus aureus* rapidly appeared [3, 6]. Because bacteria have been exposed to many of the currently available antibiotics such as β -lactams, fluoroquinolones, macrolides, tetracyclines, aminoglycosides, glycopeptides, or trimethoprim combinations for years, they have evolved resistance to these drugs due to mutation or the acquisition of genes that impart resistance from other organisms [3, 7-10]. In fact, several pathogenic bacteria, some of which were thought to have been eradicated, have made a significant resurgence due to bacterial resistance to antibiotics [3, 6]. For example, tuberculosis is currently the leading cause of death in adults by an infectious disease worldwide, which is significant given that death rates due to tuberculosis had declined to near imperceptible levels in industrial nations [11-13]. According to the CDC, several bacterial strains currently exhibit multidrug resistance with more than 60% hospital acquired infections in the United States caused by the so-called ESKAPE pathogens (E*nterococcus faecium*, S*taphylococcus aureus*, K*lebsiella pneumoniae*, A*cinetobacter baumannii*, P*seudomonas aeruginosa*, and E*nterobacter* species).

Antibiotics work by interfering with a vital bacterial cell function at a specific cellular target by either killing the bacteria or arresting their multiplication [5]. This allows the patient's immune system to clear the bacteria from the body. Inhibitors of cell wall biosynthesis (vancomycin and β -lactams, to name a few) have proven to be very potent antibiotics, evidence that interfering with cell-wall synthesis has deleterious effects on bacterial cell survival. Enzymes that are targeted by these antibiotics tend to be present in all bacteria and are highly similar in structure and function, such that certain antibiotics kill or inhibit the growth of a broad range of bacterial species (*i.e.*, broad-spectrum antibiotics) [3, 7-

10]. Unfortunately, only two new classes of anti-bacterial drugs have emerged since 1962. According to the Infectious Diseases Society of America at least ten new systemic antibacterial drugs should enter the market by the year 2020; however, most of these are derivatives of existing classes of antibiotics. Since every antibiotic has a finite lifetime, as resistance will ultimately occur particularly if the same enzymes are repeatedly targeted, development of new classes of inhibitors that target previously untargeted cellular enzymes is essential to retain control of infectious disease [14, 15].

Lysine Biosynthetic Pathway

Based on bacterial genetic information, the *meso*-diaminopimelate (*mDAP*)/lysine biosynthetic pathway offers several potential antibacterial enzyme targets that have yet to be explored (Figure 1) [16-18]. One of the products of this pathway, lysine, is required in protein synthesis and is also used in the peptidoglycan layer of Gram-positive bacterial cell walls. A second product of this pathway, *mDAP* is an essential component of the peptidoglycan cell wall for Gram-negative bacteria, providing a link between polysaccharide strands. Since lysine is an essential amino acid and is not synthesized by humans, it must be ingested. However, most bacteria, plants and algae synthesize lysine and *mDAP* from aspartic acid through three related pathways that diverge after the production of L-tetrahydrodipicolinate [16, 17, 19]. The presence of multiple biosynthetic pathways in bacteria for the synthesis of *mDAP*/lysine highlights the importance of *mDAP*/lysine for bacterial cell survival.

The succinylase pathway is the primary biosynthetic pathway for *mDAP*/lysine and is utilized by all Gram-negative and most Gram-positive bacteria [16]. The dehydrogenase pathway forms *mDAP* directly from L-tetrahydrodipicolinate but this is a high-energy transformation and is limited to only a few *Bacillus* species [16]. The acetylase pathway is

also a minor biosynthetic pathway for *mDAP* production and is also limited to only a few *Bacillus* species [17]. One of the enzymes in the succinylase pathway, the *dapE*-encoded *N*-succinyl-L,L-diaminopimelic acid desuccinylase (DapE), is a Zn(II) containing metallohydrolase. It has been shown that deletion of the gene encoding for DapE is lethal to *Helicobacter pylori* and *Mycobacterium smegmatis* [20, 21]. Even in the presence of lysine supplemented media *H. pylori* was unable to grow, suggesting that lysine can't be synthesized by other pathways or imported. Therefore, DapE's appear to be essential for cell growth and proliferation and are part of a biosynthetic pathway that is the *only* source of lysine in most bacteria. Since there are no similar biosynthetic pathways in mammals, DapE's appear to be potential targets for inhibitors that may possess antimicrobial activity [16].

DapE's Contain a Dinuclear Zn(II) Active Site

DapE's catalyze the hydrolysis of *N*-succinyl-L,L-diaminopimelic acid (L,L-SDAP), forming L,L-diaminopimelic acid and succinate (Figure 2) [19]. DapE's have been purified from multiple sources and genes identified in a large number of pathogenic Gram-positive and Gram-negative bacteria including all of the ESKAPE pathogens [20-25]. Alignment of several of the DapE gene sequences show a minimum of 49% identity [26]. Significantly, all of the residues that are metal binding ligands in the M28 family of dinuclear Zn(II)-dependent metalloproteases [27], including the aminopeptidase from *Vibrio proteolyticus* (*Aeromonas proteolytica*, AAP) and the carboxypeptidase from *Pseudomonas sp* strain-RS-16 (CPG2) [28, 29] are strictly conserved in all DapE enzymes. Since the catalytic activity of DapE's require Zn(II) and both CPG2 and AAP possess (μ -aquo)(μ -carboxylato)dizinc(II) active sites with one terminal carboxylate and one histidine residue at each metal site, a similar active site was proposed for DapE enzymes [19, 30-32]. Evidence for a dinuclear Zn(II)-active site in DapE enzymes was obtained *via* Zn K-edge Extended X-ray Absorption Fine Structure (EXAFS) spectra of the DapE from *H. influenzae* in the presence of one and two equivalents of Zn(II)

(i.e. [Zn_(DapE)] and [ZnZn(DapE)]) [33]. Fourier transforms of the Zn EXAFS are dominated by a peak at *ca.* 2.0 Å, which was best fit assuming *ca.* 5 (N,O) scatterers at 1.96 and 1.98 Å for [Zn_(DapE)] and [ZnZn(DapE)], respectively. Inclusion of a sulfur (S) atom provided poorer fits based on Debye-Waller Factors. A second-shell feature at *ca.* 3.34 Å appears in the [ZnZn(DapE)] EXAFS spectrum but is significantly diminished in [Zn_(DapE)]. These data confirmed that DapE enzymes can bind two Zn(II) ions that form a dinuclear site.

Both AAP and CPG2 contain active site His residues that function as ligands to the Zn1 and Zn2 centers. Based on sequence alignment of the DapE from *H. influenzae* with AAP and CPG2, both H67 and H349 were predicted to be Zn(II) ligands [32]. In an effort to clearly define the active site residues and provide insight into the structural properties of each divalent metal ion in DapE enzymes, the H67A and H349A DapE mutant enzymes were prepared. The H67A DapE enzyme exhibited a decrease in catalytic efficiency (~180-fold) compared to WT DapE towards the substrate L,L-SDAP. No catalytic activity was observed for H349A under the experimental conditions used. EPR and UV-Vis data indicated that the Co(II) ion bound to H349A-DapE is analogous to that of WT DapE after the addition of a *single* Co(II) ion. The addition of one equivalent of Co(II) to H67A DapE provided spectra that are very different from the first Co(II) binding site of the WT enzyme, but similar to the *second* binding site. The UV-Vis and EPR data, in conjunction with the kinetic data, are consistent with the assignment of H67 and H349 as active site metal ligands for DapE. Furthermore, these data suggest that H67 is a ligand in the *first* metal binding site while H349 resides in the *second* metal binding site.

Sequence alignment with AAP and CPG2 also suggested that the active site residue in the DapE from *H. influenzae*, E134, likely functioned as the general acid/base during the hydrolysis reaction catalyzed by DapE [19]. In order to elucidate the catalytic role of E134, the E134A and E134D mutant DapE enzymes were prepared [34]. The Michaelis constant

(K_m) was found to not change upon substitution to aspartate but the k_{cat} values changed drastically in the order: glutamate (140 s^{-1}), aspartate (0.13 s^{-1}), and alanine (none detected). Examination of the pH dependence of the kinetic constants k_{cat} and K_m for the E134D enzyme revealed ionizations at pH 6.4, 7.4, and ~ 9.7 . Isothermal titration calorimetry (ITC) studies on WT DapE provided K_d values for the first and second Zn(II) binding sites of 4.4 and 13.6 μM . ITC experiments on E134D- and E134A-DapE revealed a significant weakening in metal K_d values of 2.9 and 1.4 times for the first metal binding event, respectively. Interestingly, UV-Vis and EPR spectra obtained on Co(II)-substituted E134D and E134A DapE did not reveal any significant changes suggesting that both Co(II) ions reside in distorted trigonal bipyramidal coordination geometries [35]. Combination of these data indicates that E134 is intrinsically involved in the hydrolysis reaction catalyzed by DapE and likely plays the role of a general acid/base.

Structural Characterization of DapE Enzymes

A major limitation in developing a previously undescribed class of antimicrobials that target DapE enzymes was the lack of knowledge about their active site structure including potential residues involved in substrate binding. The X-ray crystal structure of the DapE enzyme from *N. meningitidis* was reported at 1.9 Å but was in the apo-form, providing little information about the Zn(II) active site [36]. Recently, the X-ray crystal structure of the DapE from *H. influenzae* was reported for both the mono and dinuclear Zn(II) forms at 2.0 and 2.3 Å resolution, respectively [37]. Similar to the DapE from *N. meningitidis*, the DapE from *H. influenzae* forms a homodimer where the catalytic domain consists of an α/β globular domain with a twisted β -sheet hydrophobic core sandwiched between α -helices (Figure 3). The active-site cleft is located in the center of the catalytic domain above the centrally located

parallel strands of the β -sheet and is covered by loops. The location and the architecture of the active site are strikingly similar to the active sites of CPG2 and AAP.^{28,29}

The active site of the mononuclear Zn(II) form of DapE ([Zn_(DapE)]), reveals that Zn1 resides in a distorted tetrahedral geometry coordinated by the carboxylate oxygens (OD1) of D100 and (OE1) of E163 as well as one nitrogen atom (NE2) of H67 (Figure 4). The remaining coordination site is filled by an oxygen atom provided from a water molecule. In the dinuclear Zn(II) form of DapE ([ZnZn(DapE)]), the active site contains two Zn(II) ions at a distance of 3.36 Å compared with 3.45 Å for AAP and 3.25 Å for CPG₂.^{28,29} Each of the Zn(II) ions adopts a distorted tetrahedral geometry and is coordinated by one imidazole group (H67 for Zn1 and H349 for Zn2) and one carboxylate group (E163 for Zn1 and E135 for Zn2). Both Zn(II) ions are bridged by an additional carboxylate group (D 100) on one side and water/hydroxide on the opposite side, forming a (μ -aquo)(μ -carboxylato)dizinc(II) core with one terminal carboxylate and one histidine residue at each metal site. These structures confirm the assignment of H67 and H349 as active site ligands with H67 residing in the first metal binding site as well as the role of Glu134.

Inspection of the X-ray crystal structures of [Zn_(DapE)] and [ZnZn(DapE)], combined with surface analysis, revealed a crescent-shaped cavity that extends along the catalytic domain and surrounds the active site (Figure 5). This well-defined, negatively charged cavity is shaped from the top by strand β 12 and α 8 and in the middle by the loop connecting these two elements. The bottom of the cavity is formed by a loop connecting β -strands β 6 and β 7, and a loop connecting β 5 and α 4. Taking into account the linear character of the substrate, it is likely that the substrate binds in an extended conformation [38], lining up along the groove with the peptide bond positioned over the active site metals. It is conceivable that substrate binding is further stabilized by interaction of the substrate carboxylate groups with positively charged amino acid side chains. Potential candidates include K175, R258, and

R329 (Figure 6). In the [ZnZn(DapE)] structure, R258, and R329 form a charged dipole interaction with a sulfate ion, a possible mimic of the carboxylic group of the substrate. R329 is centrally positioned in a positively charged pocket that it forms together with R258. Interestingly, the active site pocket of CPG2 contains an arginine that is conserved in DapE (R329) and has been proposed to bind the carboxylate group of the side chain. These data, in combination with previously reported inhibitor binding studies [32, 33, 39, 40], indicate that DapE represents an excellent target for a highly specific drug that should have high efficacy and low toxicity.

Proposed Catalytic Mechanism of DapE

The X-ray structures of [Zn_DapE] and [ZnZn_DapE] provide a structural foundation for a proposed reaction mechanism of DapE [19, 32, 34]. Analysis of the available structures along with the previously reported kinetic and spectroscopic data for DapE enzymes allowed a detailed mechanism of catalysis for DapE's to be proposed (Figure 7) [37]. Based on the proposed catalytic mechanism for AAP [41, 42], the first step in catalysis for DapE's is likely recognition of the L,L-SDAP side chain by the crescent-shaped cavity adjacent to the Zn1 site. Next, the peptide carbonyl oxygen of L,L-SDAP coordinates to Zn1 and expands its coordination number from four to five, activating the carbonyl for nucleophilic attack. Deprotonation of the metal-bound water molecule by E134 to form a nucleophilic hydroxide moiety is consistent with the postulated pK_a of the zinc-bound water molecule [19]. Once the zinc-bound hydroxide is formed, it can attack the activated carbonyl carbon of the substrate, forming an $-1-\mu$ -transition-state complex [33]. Solvent kinetic isotope effect studies yielded an inverse isotope effect that was explained by the attack of a zinc-bound hydroxide on the amide carbonyl [19]. E134 may provide a proton to the penultimate amino nitrogen, similar to that observed for AAP, returning it to its ionized state thus facilitating product release. Once the products are released, a water molecule bridging the two metal ions is replaced. In

the absence of a second metal ion, the catalytic mechanism does not likely change markedly as H349 is in position to assist in orienting the substrate properly in the active site through the formation of a hydrogen bond with a carboxylate side chain of the substrate, thereby stabilizing the transition-state intermediate reminiscent to proposals for the mono-metalated forms of AAP and the methionine aminopeptidase from *E. coli* [43-45]. In the presence of a dinuclear site, the second metal ion likely coordinates either the peptide carbonyl oxygen in a bridging fashion or a carboxylate side chain of the substrate.

Design and Synthesis of DapE Inhibitors

The design and synthesis of novel DapE inhibitors requires information regarding substrate specificity. Therefore, the four isomers of SDAP as well as a number of acetylated amino acids have been examined as potential substrates. DapE was not able to hydrolyze the D,D-, L,D-, or D,L-isomers of SDAP confirming that L,L-SDAP is the only known biological substrate for DapE enzymes. Moreover, no hydrolytic degradation was observed for any acetylated amino acids tested [25, 32], therefore, the DapE active site has strict substrate specificity with regard to both functional groups and stereochemistry. These data also suggest that the carboxylate of the succinyl moiety forms an important interaction within the active site of DapE since the acetylated amino acids could not be hydrolyzed.

Alternatively, the acetylated versions of these amino acids may introduce a repulsive interaction because of bulky alkyl groups, thus, preventing hydrolysis. Given the lack of hydrolytic activity towards the SDAP isoforms, a series of potential DapE inhibitors based on SDAP bearing different *N*-linked acyl side chains terminated with (i) a carboxyl group or (ii) a lipophilic moiety, were synthesized. Unfortunately, none of these compounds functioned as potent inhibitors of DapE [32, 33, 39, 40]. Finally, D,L-succinyl aminopimelate was examined, which only differs from the natural substrate, L,L-SDAP, by the absence of the

amine group on the amino acid side chain. Interestingly, DapE could not hydrolyze this compound implying that the amine provides an important interaction for substrate binding.

The next step in inhibitor design for DapE enzymes involved understanding how inhibitors bind to the active site. To date, no X-ray structural data for a DapE enzyme in the presence of an inhibitor has been reported; however, Zn K-edge EXAFS spectra of [ZnZn(DapE)] in the presence of the competitive inhibitors 2- carboxyethylphosphonic acid (CEPA; $K_i = 800 \mu\text{M}$) and 5- mercaptopentanoic acid (MSPA; $K_i = 6 \mu\text{M}$) have been reported.[33] Phosphonic acid-containing compounds have been shown to be potent inhibitors of metallohydrolases, including AAP and the bovine lens leucine aminopeptidase (bLAP) and have been used as probes of the transition-state of hydrolysis reactions. The EXAFS data for [ZnZn(DapE)]-CEPA indicate that the average coordination number of each Zn(II) ion is five, and the Zn-Zn distance remains 3.34 \AA . An increase in the M-M distance of [ZnZn(AAP)], from 3.5 to 3.9 \AA , is observed upon the addition of the transition-state analog inhibitor L-leucine- phosphonic acid (LPA), which contains a similar ligating group to CEPA [46]. The X-ray crystal structure and EXAFS data for [ZnZn(AAP)]-LPA, reveal that the bridging water molecule is displaced by LPA resulting in an η -1,2- μ -phosphonate bridge and an increase in the Zn-Zn distance of 0.4 \AA . The fact that the Zn-Zn distance is not altered upon CEPA binding to [ZnZn(DapE)] suggests an η -1- μ -phosphonate bridge exists, similar to the binding mode of LPA to bLAP [46, 47]. On the other hand, MSPA binding to [ZnZn(DapE)] has a marked effect on the Zn K-edge, suggesting that the average electronic environment of the dinuclear Zn(II) site has changed significantly. The observed shift to lower energy in the absorption edge position is indicative of a net increase in electron density at the dinuclear Zn(II) site, consistent with a sulfur ligand. In addition, the EXAFS data for [ZnZn(DapE)]-MSPA reveals a new feature at 2.3 \AA that is highly characteristic of a direct zinc-sulfur interaction. Moreover, the M-M distance is lengthened from 3.34 \AA to 3.64 \AA .

These data indicate that the thiol group of MSPA binds to one or both of the Zn(II) ions in the active site of DapE.

The fact that thiol based molecules were shown to be moderately strong inhibitors of DapE provided insight into examining bifunctional molecules that contained, in addition to a thiol zinc binding group (ZBG), a carboxylate moiety that could interact with the positively-charged lysine and arginine side chains that purportedly reside near the active site. These studies led to the identification of several low micromolar inhibitors of DapE, all of which, like MSPA, contain a thiol functional group [39]. Thiol containing compounds are typically good inhibitors of Zn(II) metalloproteins since Zn(II) is a soft acid and thiols are soft bases [48]. One of the better inhibitors was L-penicillamine (Figure 8) which exhibited an IC₅₀ value of 13.7 μ M, and a measured K_i of 4.6 μ M (competitive). DapE is stereoselective with respect to recognition of inhibitors, as D-penicillamine gave an IC₅₀ of 50 μ M. Given the success with these carboxylic acid-containing thiols, L-captopril (Figure 8) an angiotensin-converting enzyme (ACE) inhibitor was examined, which contains the requisite ZBG and carboxylate functionalities. L-Captopril exhibited an IC₅₀ of 3.3 μ M and a measured K_i of 1.8 μ M (competitive). Again, the binding is stereoselective, as D-captopril was an order of magnitude less potent, with an IC₅₀ of 42.0 μ M. Given the good potency of L-captopril, another ACE inhibitor, enalapril, was screened but did not show any potency towards DapE. 4-Mercaptobutyric acid is also an inhibitor of DapE and exhibits an IC₅₀ value of 43 μ M while 2-mercaptobenzoic acid has a measured IC₅₀ value of 34 μ M. For these low micromolar inhibitors, it was hypothesized that the presence of a negatively-charged carboxylate in the molecule participates in an ionic interaction with a positively-charged lysine or arginine near the active site.

Given that L-captopril functions as a moderately strong inhibitor of DapE, its efficacy was examined using a standard plate assay [39]. Application of L-captopril or L-

penicillamine directly to plates cultured with *E. coli* showed a dose-responsive antibiotic activity for L-captopril. Very little inhibition is observed for 1 mg of L-captopril, but 5 mg and 20 mg demonstrate a clear positive antibiotic result. These data suggest that L-captopril can cross the bacterial cell membrane and function to inhibit bacterial cell growth. Whether DapE is the cellular target of L-captopril was not addressed, however, a recent study suggested that DapE is not the main target of L-captopril antimicrobial activity since L-captopril inhibited *S. enterica* and *E. coli* in a DapE-independent manner [49]. Clearly, further studies are needed to verify DapE as an antimicrobial target and such studies will necessitate the discovery of strong binding inhibitors that are specific for DapE enzymes.

Concluding Remarks

Bacterial infections, some of which were thought to be eradicated, have made a significant resurgence due to bacterial resistance to all known antibiotics [2-4]. Consequently, new compounds that combat these pathogens and target enzymes involved in bacterial cell wall synthesis or pathways involved in cell replication are in high demand [50-57]. That the *meso*-diaminopimelate (*mDAP*)/lysine biosynthetic pathway offers several potential anti-bacterial targets that have yet to be explored. While our understanding of the catalytic mechanism of DapE has markedly improved over the past few years, it has not yet been entirely delineated. For example, several substrate binding steps have been proposed and the roles of each metal ion during catalysis are still in question. Therefore, more experimental evidence is needed to distinguish between the competing mechanistic proposals for DapE. Even so, results obtained from the studies described in this review have provided new insight into the structure and function of DapE enzymes and have led to new medicinal chemistry leads. Additional insight into the catalytic mechanism of DapE and the

determinants of substrate-binding will be critical for the rational design of future selective DapE inhibitors that may function as a new class of antimicrobial agents.

References

1. Prevention CfDCa (1995) *MMWR Morb. Mortal. Wkly Rep.* 44:1-13
2. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP (1998) *Lancet* 351:601-602
3. Levy SB (1998) *Sci. Am.* 278:46-53
4. Chin J (1996) *New Scientist* 152:32-35
5. Henery CM (2000) *C&E News* 78:41-58
6. Nemecek S (1997) *Sci. Am.* 276:38-39
7. Miller JB (2000) *The Pharmaceutical-Century: Ten Decades of Drug Discovery; Supplement to ACS: Washington DC*, pp. 52-71
8. Lesney MS, Frey R (2000) *The Pharmaceutical-Century: Ten Decades of Drug Discovery; Supplement to ACS: Washington DC*, pp. 110-129
9. Frey R, Lesney MS (2000) *The Pharmaceutical-Century: Ten Decades of Drug Discovery; Supplement to ACS: Washington DC*, pp. 92-109
10. Tweedy BD, Lesney MS (2000) *The Pharmaceutical-Century: Ten Decades of Drug Discovery; Supplement to ACS: Washington DC*, pp. 72-91
11. Snider DE, Raviglione M, Kochi A (1994) In: Bloom BR (ed) *Global burden of tuberculosis*. ASM Press, Washington DC, pp. 3-11
12. Dolin PJ, Raviglione MC, Kochi A (1994) *Bull. W. H. O.* 72:213-220
13. Raviglione MC, Snider DE, Kochi A (1995) *JAMA* 273:220-226
14. Teuber M (1999) *Cell. Mol. Life Sci.* 56:755-763
15. Miller JR, Dunham S, Mochalkin I, Banotai C, Bowman M, Buist S, Dunkle B, Hanna D, Harwood HJ, Huband MD, Karnovsky A, Kuhn M, Limberakis C, Liu JY, Mehrens S, Mueller WT, Narasimhan L, Ogden A, Ohren J, Prasad JV, Shelly JA, Skerlos L, Sulavik M, Thomas VH, VanderRoest S, Wang L, Wang Z, Whitton A, Zhu T, Stover CK (2009) *Proc Natl Acad Sci U S A.* 106:1737-1742 DOI 10.1073/pnas.0811275106
16. Scapin G, Blanchard JS (1998) *Adv. Enzymol.* 72:279-325
17. Born TL, Blanchard JS (1999) *Cur. Opin. Chem. Biol.* 3:607-613

18. Girodeau J-M, Agouridas C, Masson M, R. P, LeGoffic F (1986) *J. Med. Chem.* 29:1023-1030
19. Born TL, Zheng R, Blanchard JS (1998) *Biochemistry* 37:10478-10487
20. Karita M, Etterbeek ML, Forsyth MH, Tummuru MR, Blaser MJ (1997) *Infect. Immun.* 65:4158-4164
21. Pavelka MS, Jacobs WR (1996) *J. Bacteriol.* 178:6496-6507
22. Bouvier J, Richaud C, Higgins W, Bögler O, Stragier P (1992) *J. Bacteriol.* 174:5265-5271
23. Fuchs TM, Schneider B, Krumbach K, Eggeling L, Gross R (2000) *J. Bacteriol.* 182:3626-3631
24. Shaw-Reid CA, McCormick MM, Sinskey AJ, Stephanopoulos G (1999) *Appl. Microbiol. Biotechnol.* 51:325-333
25. Lin Y, Myhrman R, Schrag ML, Gelb MH (1988) *J. Biol. Chem.* 263:1622-1627
26. Gillner DM, Bienvenue DL, Nocek BP, Joachimiak A, Zachary V, Bennett B, Holz RC (2009) *J. Biol. Inorg. Chem.* 14:1-10
27. Barrett AJ, Rawlings ND, Woessner JF (eds) (1998) *Handbook of Proteolytic Enzymes.* Academic Press, London
28. Rowsell S, Pauptit RA, Tucker AD, Melton RG, Blow DM, Brick P (1997) *Structure* 5:337-347
29. Desmarais W, Bienvenue DL, Bzymek KP, Petsko GA, Ringe D, Holz RC (2006) *J. Biol. Inorg. Chem.* 11:398-408
30. Chevrier B, Schalk C, D'Orchymont H, Rondeau J-M, Moras D, Tarnus C (1994) *Structure* 2:283-291
31. Greenblatt HM, Almog O, Maras B, Spungin-Bialik A, Barra D, Blumberg S, Shoham G (1997) *J. Mol. Biol.* 265:620-636
32. Bienvenue DL, Gilner DM, Davis RS, Bennett B, Holz RC (2003) *Biochemistry* 42:10756-10763
33. Cospér NJ, Bienvenue DL, Shokes JE, Gilner DM, Tsukamoto T, Scott R, Holz RC (2003) *J. Am. Chem. Soc.* 125:14654-14655

34. Davis R, Bienvenue D, Swierczek SI, Gilner DM, Rajagopal L, Bennett B, Holz RC (2006) *J. Biol. Inorg. Chem.* 11:206-216
35. Bennett B (2010) In: Hanson G, Berliner L (eds) *Biol. Magn. Reson., Metals in Biology*. Springer, New York, pp. 345-370
36. Badger J, Sauder JM, Adams JM, Antonysamy S, Bain K, Bergseid MG, Buchanan SG, Buchanan MD, Batiyenko Y, Christopher JA, Emtage S, Eroshkina A, Feil I, Furlong EB, Gajiwala KS, Gao X, He D, Hendle J, Huber A, Hoda K, Kearins P, Kissinger C, Laubert B, Lewis HA, Lin J, Loomis K, Lorimer D, Louie G, Maletic M, Marsh CD, Miller I, Molinari J, Muller-Dieckmann HJ, Newman JM, Noland BW, Pagarigan B, Park F, Peat TS, Post KW, Radojicic S, Ramos A, Romero R, Rutter ME, Sanderson WE, Schwinn KD, Tresser J, Winhoven J, Wright TA, Wu L, Xu J, Harris TJ (2005) *Proteins* 60:787-796
37. Nocek BP, Gillner DM, Fan Y, Holz RC, Joachimiak A (2010) *J. Mol. Biol.* 397:617-626 DOI 10.1016/j.jmb.2010.01.062
38. Tyndall JDA, Nall T, Fairlie DP (2005) *Chem. Rev.* 105:973-999
39. Gillner DM, Armush N, Holz RC, Becker D (2009) *Bioorg. Med. Chem. Lett.* 19:6350-6352
40. Vaněk V, Pícha J, Buděšínský M, Šanda M, Jiráček J, Holz RC, Hlaváček J (2010) *Protein Pept. Lett.* 17:405-409
41. Ustynyuk L, Bennett B, Edwards T, Holz RC (1999) *Biochemistry* 38:11433-11439
42. Stamper CC, Bienvenue DL, Moulin A, Bennett B, Ringe D, Petsko GA, Holz RC (2004) *Biochemistry* 43:9620-9628
43. Copik AJ, Swierczek SI, Lowther WT, D'souza VM, Matthews BW, Holz RC (2003) *Biochemistry* 42:6283-6292
44. Ye QZ, Xie SX, Ma ZQ, Huang M, Hanzlik RP (2006) *Proc Natl Acad Sci U S A.* 103:9470-9475
45. Holz RC (2002) *Coord. Chem. Rev* 232:5-26
46. Stamper CC, Bennett B, Edwards T, Holz RC, Ringe D, Petsko GA (2001) *Biochemistry* 40:7035-7046

47. Sträter N, Lipscomb WN (1995) *Biochemistry* 34:9200-9210
48. Jacobsen FE, Lewis JA, Cohen SM (2007) *ChemMedChem* 2:152-171
49. Uda NR, Creus M (2011) *Bioinorganic Chemistry and Applications* 2011:6 DOI 10.1155/2011/306465
50. Arfin SM, Kendall RL, Hall L, Weaver LH, Stewart AE, Matthews BW, Bradshaw RA (1995) *Proc. Natl. Acad. Sci. USA* 92:7714-7718
51. Ben-Bassat A, Bauer AK, Chang S-Y, Myambo K, Boosman A, Chang S (1987) *J. Bacteriol.* 169:751-757
52. Ben-Bassat A, Bauer K (1987) *Nature* 326:315
53. Chang S-Y, McGary EC, Chang S (1989) *J. Bacteriol* 171:4071-4072
54. Gonzales T, Robert-Baudouy J (1996) *FEMS Microbiol. Rev.* 18:319-344
55. Taylor A (1993) *FASEB J.* 7:290-298
56. Taylor A (1993) *TIBS* 18:167-172
57. Taylor A (ed) (1996) *Aminopeptidases*. R. G. Landes Co., Austin, TX USA
58. Molecular graphics and analyses were performed with the UCSF Chimera package (<http://www.cgl.ucsf.edu/chimera>). Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institutes of Health (National Center for Research Resources grant 2P41RR001081, National Institute of General Medical Sciences grant 9P41GM103311).

Figure Captions

Figure 1. Biosynthetic pathways of *meso*-diaminopimelic acid and lysine in bacteria.

Figure 2. Reaction catalyzed by DapE.

Figure 3. Ribbon diagram of the X-ray crystal structure of the DapE from *H. influenzae* showing the dimer and catalytic structural domains. Zinc ions are labeled in black (Zn1-the catalytic zinc) and grey (Zn2) [58].

Figure 4. Active site of the A) Zn_DapE and B) ZnZnDapE from *H. influenzae* [58].

Figure 5. Surface rendering of [ZnZn(DapE)] from *H. influenzae* showing the charge distribution and depicting the crescent-shaped active site cavity [58].

Figure 6. Charged residues near the dinuclear active site of DapE that may play a role in substrate recognition and binding process [58].

Figure 7. Proposed catalytic mechanism of DapE.

Figure 8. Structures of L-captopril and L-penicillamine.

Figure 1




Figure 2




Figure 3





Figure 4

A



B




Figure 5




Figure 6




Figure 7




Figure 8

